<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31603947</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>12</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Current status and direct medical cost of amyotrophic lateral sclerosis in the region of Catalonia: A population-based analysis.</ArticleTitle><Pagination><StartPage>e0223772</StartPage><MedlinePgn>e0223772</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0223772</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0223772</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Amyotrophic lateral sclerosis is a neurodegenerative disease that leads to motor weakness. There is no cure, and treatment focuses on slowing down progression, which is achieved by a multidisciplinary approach. Hence, it is vital to understand the population needs for an optimal management of the disease.</AbstractText><AbstractText Label="OBJECTIVES">To evaluate the current status of amyotrophic lateral sclerosis in the region of Catalonia, how the disease is managed and its direct medical costs.</AbstractText><AbstractText Label="METHODS">Records corresponding to 841 patients diagnosed between the year 2007 and 2017 were analysed in a retrospective population-based study, including data from primary care centres, hospitals (inpatient and outpatient care), extended care facilities and mental health centres.</AbstractText><AbstractText Label="RESULTS">Mean diagnosis age was 66.11 years (SD = 12.61) and 52.79% of admitted patients were males. On average, 14.91 months elapsed between diagnosis and death, and the mean age of death was 72.64 years (SD = 12.00). Patients were admitted 10.70 times per year, mostly into primary care (86.50%), although most expenses were concentrated in hospital inpatient care. The mean cost per patient per year was &#x20ac;1,168. The 83.24% of patients had more than 4 systems affected by chronic conditions.</AbstractText><AbstractText Label="CONCLUSIONS">Primary care is of utmost importance in ALS attention in Catalonia, which may have a direct impact in reducing hospitalisation costs. Nonetheless, the expenses linked to inpatient care represent the biggest portion of total costs. Patients' healthcare usage patterns and the high proportion of patients with multiple chronic conditions should be taken into account in order to adapt and improve guidelines and healthcare systems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Darb&#xe0;</LastName><ForeName>Josep</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-2371-0999</Identifier><AffiliationInfo><Affiliation>Universitat de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008499" MajorTopicYN="N">Medical Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31603947</ArticleId><ArticleId IdType="pmc">PMC6788732</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0223772</ArticleId><ArticleId IdType="pii">PONE-D-19-07996</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017. October 5; 3:17071 10.1038/nrdp.2017.71</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.71</ArticleId><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis S, Goizet C, Soulages A, Vallat JM, Masson GL. Genetics of amyotrophic lateral sclerosis: A review. J Neurol Sci. 2019. February 21; 399:217&#x2013;26. 10.1016/j.jns.2019.02.030</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.02.030</ArticleId><ArticleId IdType="pubmed">30870681</ArticleId></ArticleIdList></Reference><Reference><Citation>Grad LI, Rouleau GA, Ravits J, Cashman NR. Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS). Cold Spring Harb Perspect Med. 2017. August 1; 7(8).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538408</ArticleId><ArticleId IdType="pubmed">28003278</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, Chi&#xf2; A, Mitchell D, Swingler RJ et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010. April; 81(4):385&#x2013;90. 10.1136/jnnp.2009.183525</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.183525</ArticleId><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Bastida J, Perestelo-P&#xe9;rez L, Mont&#xf3;n-&#xc1;lvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain. Amyotroph Lateral Scler. 2009. August; 10(4):237&#x2013;43. 10.1080/17482960802430781</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802430781</ArticleId><ArticleId IdType="pubmed">18821088</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Campo Y, Homedes C, Lazaro A, Alarc&#xf3;n R, Campo D, Riera M, Dom&#xed;nguez R, Povedano M, Casasnovas C. Observational study of patients in Spain with amyotrophic lateral sclerosis: correlations between clinical status, quality of life, and dignity. BMC Palliat Care. 2017; 16: 75 10.1186/s12904-017-0260-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12904-017-0260-6</ArticleId><ArticleId IdType="pmc">PMC5735656</ArticleId><ArticleId IdType="pubmed">29258495</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriani MH, Desnuelle C. Care management in amyotrophic lateral sclerosis. Rev Neurol (Paris). 2017. May; 173(5):288&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">28461024</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health. 2007. Sep-Oct; 10(5):326&#x2013;35. 10.1111/j.1524-4733.2007.00186.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1524-4733.2007.00186.x</ArticleId><ArticleId IdType="pubmed">17888097</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalunya. RESOLUCI&#xd3; SLT/353/2013, de 13 de febrer, sobre la revisi&#xf3; de preus p&#xfa;blics corresponents als serveis sanitaris que presta l&#x2019;Institut Catal&#xe0; de la Salut. (DOGC n&#xfa;m. 6326&#x2013;1.3.2013).</Citation></Reference><Reference><Citation>Catalunya. Ordre SLT/235/2013, de 9 de setembre, per la qual s'estableixen per a l'any 2013 els valors de les unitats de pagament per a la contraprestaci&#xf3; dels serveis duts a terme pels centres sociosanitaris (DOGC n&#xfa;m. 6478&#x2013;11.10.2013).</Citation></Reference><Reference><Citation>Monterde D, Vela E, Cl&#xe8;ries M, grupo colaborativo GMA. Adjusted morbidity groups: A new multiple morbidity measurement of use in Primary Care. Atenci&#xf3;n Primaria. 2016; 48(10):674&#x2013;82. 10.1016/j.aprim.2016.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.aprim.2016.06.003</ArticleId><ArticleId IdType="pmc">PMC6879171</ArticleId><ArticleId IdType="pubmed">27495004</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, Lozano-Cuesta P, Santurt&#xfa;n A, S&#xe1;nchez-Juan P, L&#xf3;pez-Vega JM, Berciano J, et al. Amyotrophic Lateral Sclerosis in Northern Spain 40 Years Later: What Has Changed? Neurodegener Dis. 2016; 16(5&#x2013;6):337&#x2013;41. 10.1159/000445750</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000445750</ArticleId><ArticleId IdType="pubmed">27188850</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Tsuda K, Takahashi F, Hirai M, Palumbo J. An assessment of treatment guidelines, clinical practices, demographics, and progression of disease among patients with amyotrophic lateral sclerosis in Japan, the United States, and Europe. Amyotroph Lateral Scler Frontotemporal Degener. 2017. October; 18(sup1):88&#x2013;97. 10.1080/21678421.2017.1361445</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361445</ArticleId><ArticleId IdType="pubmed">28872912</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009. Oct-Dec; 10(5&#x2013;6):310&#x2013;23. 10.3109/17482960802566824</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Borkan J, Eaton CB, Novillo-Ortiz D, Rivero Corte P, Jadad AR. Renewing primary care: lessons learned from the Spanish health care system. Health Aff (Millwood). 2010. August; 29(8):1432&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">20679646</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CE, McVey AL, Rudnicki S, Dimachkie MM, Barohn RJ. Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis. Neurol Clin. 2015. November; 33(4):889&#x2013;908. 10.1016/j.ncl.2015.07.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2015.07.010</ArticleId><ArticleId IdType="pmc">PMC5031364</ArticleId><ArticleId IdType="pubmed">26515628</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidelines for the treatment of amyotrophic lateral sclerosis (ALS) in Spain. [Gu&#xed;a para la atenci&#xf3;n de la esclerosis lateral amiotr&#xf3;fica (ELA) en Espa&#xf1;a]. Spanish Ministry of Health, 2009.</Citation></Reference><Reference><Citation>Andersen PM, Borasio GD, Dengler R, Hardiman O, Kollewe K, Leigh PN, et al. EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives. Eur J Neurol. 2005. December; 12(12):921&#x2013;38. 10.1111/j.1468-1331.2005.01351.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2005.01351.x</ArticleId><ArticleId IdType="pubmed">16324086</ArticleId></ArticleIdList></Reference><Reference><Citation>Diagnosis and treatment of amyotrophic lateral sclerosis. [Diagn&#xf2;stic i tractament de l&#x2019;esclerosi lateral amiotr&#xf2;fica]. Catalan Society of Neurology, 2011.</Citation></Reference><Reference><Citation>Report of the Project of Stratification of the Population in GMA groups in the National Health System (2014&#x2013;2016). [Informe del proyecto de Estratificaci&#xf3;n de la Poblaci&#xf3;n por Grupos de Morbilidad Ajustados (GMA) en el Sistema Nacional de Salud (2014&#x2013;2016)]. Spanish Ministry of Health, 2018.</Citation></Reference><Reference><Citation>Turner MR, Goldacre R, Ramagopalan S, Talbot K, Goldacre MJ. Autoimmune disease preceding amyotrophic lateral sclerosis: an epidemiologic study. Neurology. 2013. October 1; 81(14): 1222&#x2013;5. 10.1212/WNL.0b013e3182a6cc13</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a6cc13</ArticleId><ArticleId IdType="pmc">PMC3795611</ArticleId><ArticleId IdType="pubmed">23946298</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunton A, Hansen G, Schellenberg KL. Hospital utilization for patients with amyotrophic lateral sclerosis in saskatoon, Canada. Amyotroph Lateral Scler Frontotemporal Degener. 2018. May; 19(3&#x2013;4):201&#x2013;205. 10.1080/21678421.2017.1400071</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1400071</ArticleId><ArticleId IdType="pubmed">29160128</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA. Diagnosis and Clinical Management of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. Continuum (Minneap Minn). 2017. October; 23(5, Peripheral Nerve and Motor Neuron Disorders):1332&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">28968365</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>